OBJECTIVE: The Lesotho Population-based HIV Impact Assessment survey was conducted nationally and designed to measure HIV prevalence, incidence, and viral load suppression (VLS). DESIGN: A nationally representative sample of 9403 eligible households was surveyed between November 2016 and May 2017; analyses account for study design. Consenting participants provided blood samples, socio-demographic, and behavioral information. METHODS: Blood samples were tested using the national rapid HIV testing algorithm. HIV-seropositive results were confirmed with Geenius supplemental assay. Screening for detectable concentrations of antiretroviral analytes was conducted on dried blood specimens from all HIV-positive adults using high-resolution liquid chromatography coupled with tandem mass spectrometry. Self-reported and/or antiretroviral biomarker data were used to classify individuals as HIV-positive and on treatment. Viral load testing was performed on all HIV-positive samples at central labs. VLS was defined as HIV RNA below 1000 copies/ml. RESULTS: Overall, 25.6% of adults aged 15-59 years were HIV-positive. Among seropositive adults, 81.0% (male 76.6%, female 84.0%) reported knowing their HIV status, 91.8% of people living with HIV (male 91.6%, female 92.0%) who reported knowing their status reporting taking antiretrovirals, and 87.7% (male and female 87.7%) of these had VLS. Younger age was significantly associated with being less likely to be aware of HIV status for both sexes. CONCLUSIONS: Findings from this population-based survey provide encouraging data in terms of HIV testing and treatment uptake and coverage. Specific attention to reaching youth to engage them in HIV-related interventions are critical to achieving epidemic control.
OBJECTIVE: The Lesotho Population-based HIV Impact Assessment survey was conducted nationally and designed to measure HIV prevalence, incidence, and viral load suppression (VLS). DESIGN: A nationally representative sample of 9403 eligible households was surveyed between November 2016 and May 2017; analyses account for study design. Consenting participants provided blood samples, socio-demographic, and behavioral information. METHODS: Blood samples were tested using the national rapid HIV testing algorithm. HIV-seropositive results were confirmed with Geenius supplemental assay. Screening for detectable concentrations of antiretroviral analytes was conducted on dried blood specimens from all HIV-positive adults using high-resolution liquid chromatography coupled with tandem mass spectrometry. Self-reported and/or antiretroviral biomarker data were used to classify individuals as HIV-positive and on treatment. Viral load testing was performed on all HIV-positive samples at central labs. VLS was defined as HIV RNA below 1000 copies/ml. RESULTS: Overall, 25.6% of adults aged 15-59 years were HIV-positive. Among seropositive adults, 81.0% (male 76.6%, female 84.0%) reported knowing their HIV status, 91.8% of people living with HIV (male 91.6%, female 92.0%) who reported knowing their status reporting taking antiretrovirals, and 87.7% (male and female 87.7%) of these had VLS. Younger age was significantly associated with being less likely to be aware of HIV status for both sexes. CONCLUSIONS: Findings from this population-based survey provide encouraging data in terms of HIV testing and treatment uptake and coverage. Specific attention to reaching youth to engage them in HIV-related interventions are critical to achieving epidemic control.
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Andrea A Kim; Irene Mukui; Peter W Young; Joy Mirjahangir; Sophie Mwanyumba; Joyce Wamicwe; Nancy Bowen; Lubbe Wiesner; Lucy Ng'ang'a; Kevin M De Cock Journal: AIDS Date: 2016-11-13 Impact factor: 4.177
Authors: Alexandra Jones; Ide Cremin; Fareed Abdullah; John Idoko; Peter Cherutich; Nduku Kilonzo; Helen Rees; Timothy Hallett; Kevin O'Reilly; Florence Koechlin; Bernhard Schwartlander; Barbara de Zalduondo; Susan Kim; Jonathan Jay; Jacqueline Huh; Peter Piot; Mark Dybul Journal: Lancet Date: 2014-04-14 Impact factor: 79.321
Authors: Chloe A Teasdale; Elaine J Abrams; Katharine A Yuengling; Matthew R Lamb; Chunhui Wang; Mirriah Vitale; Mark Hawken; Zenebe Melaku; Harriet Nuwagaba-Biribonwoha; Wafaa M El-Sadr Journal: PLoS One Date: 2020-04-16 Impact factor: 3.240
Authors: Maria F Nardell; Oluwatomi Adeoti; Carson Peters; Bernard Kakuhikire; Caroline Govathson-Mandimika; Lawrence Long; Sophie Pascoe; Alexander C Tsai; Ingrid T Katz Journal: J Int AIDS Soc Date: 2022-03 Impact factor: 5.396
Authors: Marc d'Elbée; Molemo Charles Makhetha; Makhahliso Jubilee; Matee Taole; Cyril Nkomo; Albert Machinda; Mphotleng Tlhomola; Linda A Sande; Gabriela B Gomez Guillen; Elizabeth L Corbett; Cheryl C Johnson; Karin Hatzold; Gesine Meyer-Rath; Fern Terris-Prestholt Journal: AIDS Date: 2020-11-15 Impact factor: 4.632